Schwarz Theresa, Montanari Floriane, Cseke Anna, Wlcek Katrin, Visvader Lene, Palme Sarah, Chiba Peter, Kuchler Karl, Urban Ernst, Ecker Gerhard F
Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstraße 14, 1090, Vienna, Austria.
Department of Medicinal Chemistry, Medical University Vienna, Währingerstraße 10, 1090, Vienna, Austria.
ChemMedChem. 2016 Jun 20;11(12):1380-94. doi: 10.1002/cmdc.201500592. Epub 2016 Mar 10.
The transmembrane ABC transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are widely recognized for their role in cancer multidrug resistance and absorption and distribution of compounds. Furthermore, they are linked to drug-drug interactions and toxicity. Nevertheless, due to their polyspecificity, a molecular understanding of the ligand-transporter interaction, which allows designing of both selective and dual inhibitors, is still in its infancy. This study comprises a combined approach of synthesis, in silico prediction, and in vitro testing to identify molecular features triggering transporter selectivity. Synthesis and testing of a series of 15 propafenone analogues with varied rigidity and basicity of substituents provide first trends for selective and dual inhibitors. Results indicate that both the flexibility of the substituent at the nitrogen atom, as well as the basicity of the nitrogen atom, trigger transporter selectivity. Furthermore, inhibitory activity of compounds at P-gp seems to be much more influenced by logP than those at BCRP. Exploiting these differences further should thus allow designing specific inhibitors for these two polyspecific ABC-transporters.
跨膜ABC转运蛋白P-糖蛋白(P-gp)和乳腺癌耐药蛋白(BCRP)因其在癌症多药耐药性以及化合物吸收和分布中的作用而广为人知。此外,它们还与药物相互作用和毒性有关。然而,由于它们的多特异性,对配体-转运蛋白相互作用的分子理解仍处于起步阶段,而这种理解有助于设计选择性和双重抑制剂。本研究采用合成、计算机预测和体外测试相结合的方法来确定触发转运蛋白选择性的分子特征。对一系列15种具有不同取代基刚性和碱性的普罗帕酮类似物进行合成和测试,为选择性和双重抑制剂提供了初步趋势。结果表明,氮原子上取代基的灵活性以及氮原子的碱性都会触发转运蛋白的选择性。此外,化合物对P-gp的抑制活性似乎比其对BCRP的抑制活性受logP的影响更大。因此,进一步利用这些差异应该能够为这两种多特异性ABC转运蛋白设计出特异性抑制剂。